Health-related quality of life among extrapulmonary tuberculosis patients and inequalities by disease manifestations: a longitudinal study analysing the impact of TB treatment.

Publication date: Dec 05, 2024

To understand the impact of extrapulmonary tuberculosis (EPTB) and its treatment on quality of life, we analysed patient-reported outcome measures (PROMs) among presumptive ETPB patients. EuroQol’s five-dimensional three-level (EQ-5D-3L) questionnaire and the Visual Analogue Scale (EQ-VAS) were used to measure PROMs by 274 presumptive EPTB patients at pre- and post-treatment stages. The patients were categorised as TB and non-TB by using a composite reference standard. Following the EuroQol suggested analysis methods, we calculated the health utility summary measure at the pre- and post-treatment stages. The health state density curve and index were used to analyse inequality in reported health profiles. We investigated factors associated with EPTB patients’ health utility through multivariable regression at the pre-treatment stage. The analysis of PROMs showed both physical (mobility, self-care, usual activities) and psychological (pain, discomfort, anxiety & depression) health affected by all EPTB manifestations (lymphadenitis, pleuritis, meningitis and others). Moreover, we found inequality in reported health profiles across disease manifestations at pre- and post-treatment stages. Post-treatment, we found improvement in PROMs and no reports of extreme-level health problems. However, some problems persisted across all dimensions of EPTB manifestations. We found 100% improvement in pleuritis and meningitis manifestations. Socioeconomic status, type of health facility attended, and patients’ working capacity were associated with health utility. Despite post-treatment improvement in health, inequality of reported health states by EPTB manifestations persisted, though decreased. This highlights that holistic patient- and health system-level interventions addressing the impact of illness should consider EPTB by its manifestations, not as a single disease entity.

Open Access PDF

Concepts Keywords
Euroqol EPTB
Holistic Extrapulmonary Tuberculosis
Patients HRQoL
Proms Inequalities
Tuberculosis PROMs
Quality of Life

Semantics

Type Source Name
disease IDO quality
disease MESH extrapulmonary tuberculosis
disease MESH anxiety
disease MESH depression
disease MESH lymphadenitis
disease MESH pleuritis
disease MESH meningitis
disease IDO facility
disease IDO entity
disease MESH health inequality
disease MESH pulmonary tuberculosis
disease MESH Tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Stavudine
disease MESH delayed treatment
drug DRUGBANK Tropicamide
drug DRUGBANK 5-amino-1 3 4-thiadiazole-2-thiol
drug DRUGBANK Etoperidone
disease IDO history
drug DRUGBANK Ranitidine
disease MESH privacy
disease IDO process
drug DRUGBANK Trestolone
drug DRUGBANK Aspartame
disease IDO country
drug DRUGBANK Coenzyme M
drug DRUGBANK Esomeprazole
disease MESH weight loss
disease IDO site
disease MESH ascites
disease MESH osteomyelitis
disease MESH Marital status
disease MESH amenorrhea
disease MESH tics
drug DRUGBANK Cysteamine
drug DRUGBANK L-Valine
drug DRUGBANK Ilex paraguariensis leaf
disease MESH morbidity
disease MESH Infectious Diseases
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
disease MESH tuberculous lymphadenitis
drug DRUGBANK Naproxen
pathway REACTOME Reproduction
disease MESH Neglected Tropical Diseases
drug DRUGBANK Guanosine
disease MESH Lung Disease

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *